Vanguard Mega Cap Growth ETF (MGK) Stock Price Today
Aura AI Summary
Key Stats
- $33.70BMarket Cap
- 1,362,010Volume
- Broad Market / FactorSector
- $95.1152W High
- $70.7052W Low
- 45 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track Vanguard Mega Cap Growth ETF (MGK) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vanguard Mega Cap Growth ETF has traded between a low of $70.7 and a high of $95.11, highlighting its annual price range. Buy and sell Vanguard Mega Cap Growth ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Most Recent News
ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...

Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.
The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...

New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.
MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.